Sanofi-Aventis Zimulti (correction)
Executive Summary
Zimulti (rimonabant) is a CB-1 receptor antagonist; a recent article in "The Pink Sheet" mischaracterized the product. Rimonabant is "approvable" at FDA for obesity and "not approvable" for smoking cessation (1"The Pink Sheet" May 7, 2007, p. 25)...